Equities research analysts expect Rockwell Medical Inc (NASDAQ:RMTI) to announce ($0.13) earnings per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Rockwell Medical’s earnings, with the highest EPS estimate coming in at ($0.11) and the lowest estimate coming in at ($0.14). Rockwell Medical posted earnings of ($0.09) per share in the same quarter last year, which would suggest a negative year over year growth rate of 44.4%. The firm is scheduled to report its next quarterly earnings results on Tuesday, May 8th.
According to Zacks, analysts expect that Rockwell Medical will report full-year earnings of ($0.36) per share for the current financial year, with EPS estimates ranging from ($0.46) to ($0.26). For the next financial year, analysts forecast that the company will report earnings of $0.04 per share. Zacks’ earnings per share averages are a mean average based on a survey of research firms that follow Rockwell Medical.
Rockwell Medical (NASDAQ:RMTI) last announced its quarterly earnings results on Thursday, March 15th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.05). Rockwell Medical had a negative net margin of 45.24% and a negative return on equity of 61.67%. The firm had revenue of $14.84 million for the quarter, compared to the consensus estimate of $13.20 million. During the same period in the previous year, the company posted ($0.10) earnings per share. Rockwell Medical’s quarterly revenue was up 10.5% on a year-over-year basis.
A number of equities analysts recently commented on the company. BidaskClub raised Rockwell Medical from a “sell” rating to a “hold” rating in a research note on Tuesday, March 13th. ValuEngine lowered Rockwell Medical from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. Finally, Zacks Investment Research lowered Rockwell Medical from a “hold” rating to a “sell” rating in a research note on Thursday, January 4th.
Hedge funds and other institutional investors have recently modified their holdings of the company. Raymond James Financial Services Advisors Inc. purchased a new stake in shares of Rockwell Medical in the third quarter worth approximately $107,000. MetLife Investment Advisors LLC purchased a new stake in shares of Rockwell Medical in the fourth quarter worth approximately $110,000. Goldman Sachs Group Inc. raised its holdings in shares of Rockwell Medical by 117.3% in the fourth quarter. Goldman Sachs Group Inc. now owns 27,139 shares of the company’s stock worth $158,000 after buying an additional 14,648 shares during the period. Millennium Management LLC purchased a new stake in shares of Rockwell Medical in the fourth quarter worth approximately $217,000. Finally, Deutsche Bank AG raised its holdings in shares of Rockwell Medical by 107.7% in the fourth quarter. Deutsche Bank AG now owns 121,202 shares of the company’s stock worth $704,000 after buying an additional 62,842 shares during the period. Hedge funds and other institutional investors own 21.52% of the company’s stock.
Rockwell Medical stock traded up $0.49 during midday trading on Tuesday, reaching $5.83. 444,199 shares of the stock traded hands, compared to its average volume of 254,031. Rockwell Medical has a 12 month low of $4.84 and a 12 month high of $8.98. The firm has a market cap of $272.82, a PE ratio of -11.43 and a beta of 2.19.
TRADEMARK VIOLATION WARNING: This article was originally reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://www.thelincolnianonline.com/2018/04/17/0-13-eps-expected-for-rockwell-medical-inc-rmti-this-quarter.html.
About Rockwell Medical
Rockwell Medical, Inc (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with MarketBeat.com's FREE daily email newsletter.